DMPI DelMar Pharmaceuticals Inc gains 22% Jan 29, 2021

DelMar Pharmaceuticals, Inc., a clinical stage company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; and collaboration with the University of Texas MD Anderson Cancer Center. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/DMPI-DelMar-Pharmaceuticals-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2021011520210129.html